The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease

EMBO Molecular Medicine

Volumn 8, Issue 7, 2016, Pages 688-701

  Kessler, Thorsten ^a   Vilne, Baiba ^a   Schunkert, Heribert ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

atherosclerosis; coronary artery disease; genome wide association studies; myocardial infarction

Indexed keywords

APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; CYCLIC GMP; LIPOPROTEIN A; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; RIOCIGUAT; TRIACYLGLYCEROL; VOLANESORSEN;

ANGPTL4 GENE; APOA5 GENE; APOC3 GENE; BLOOD PRESSURE; CHOLESTEROL METABOLISM; CORONARY ARTERY DISEASE; EXOME WIDE ASSOCIATION STUDY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC PROCEDURES; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; HEART INFARCTION; HUMAN; INFLAMMATION; LIPID METABOLISM; LPA GENE; LPL GENE; MOLECULAR PATHOLOGY; PCSK9 GENE; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR DISEASE; VASCULAR REMODELLING;

EID: 84977636037     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201506174     Document Type: Review

References (93)

1. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D et al (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34: 154–156
2. Ahluwalia A, Foster P, Scotland RS, McLean PG, Mathur A, Perretti M, Moncada S, Hobbs AJ (2004) Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci USA 101: 1386–1391
3. Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang EQ, Plowchalk D, Sweeney K, Kaila N, Vincent J, Bays H (2015) Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol 115: 1212–1221
4. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, Julier C, Morahan G, Nerup J, Nierras C et al (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41: 703–707
5. Barrett JC, Dunham I, Birney E (2015) Using human genetics to make new medicines. Nat Rev Genet 16: 561–562
6. Bauer RC, Tohyama J, Cui J, Cheng L, Yang J, Zhang X, Ou K, Paschos GK, Zheng XL, Parmacek MS et al (2015) Knockout of adamts7, a novel CAD locus in humans, reduces atherosclerosis in mice. Circulation 131: 1202–1213
7. Bjoerkegren JL, Kovacic JC, Dudley JT, Schadt EE (2015) Genome-wide significant loci: how important are they? Systems genetics to understand heritability of coronary artery disease and other common complex disorders. J Am Coll Cardiol 65: 830–845
8. Braenne I, Civelek M, Vilne B, Di Narzo A, Johnson AD, Zhao Y, Reiz B, Codoni V, Webb TR, Foroughi Asl H et al (2015) Prediction of causal candidate genes in coronary artery disease loci. Arterioscler Thromb Vasc Biol 35: 2207–2217
9. Brautbar A, Ballantyne CM (2011) Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol 8: 253–265
10. C Reactive Protein Coronary Heart Disease Genetics Collaboration C (2011) Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 342: d548
11. Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S, AmiGO Hub, Web Presence Working Group (2009) AmiGO: online access to ontology and annotation data. Bioinformatics 25: 288–289
12. CARDIoGRAMplusC4D Consortium (2013) Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 45: 25–33
13. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354: 1264–1272
14. Concannon P, Rich SS, Nepom GT (2009) Genetics of type 1A diabetes. N Engl J Med 360: 1646–1654
15. Coronary Artery Disease C4D Genetics Consortium (2011) A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet 43: 339–344
16. Crossey E, Amar MJA, Sampson M, Peabody J, Schiller JT, Chackerian B, Remaley AT (2015) A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine 33: 5747–5755
17. Davignon J (2004) Role of endothelial dysfunction in atherosclerosis. Circulation 109: III–27–III–32
18. Desai U, Lee EC, Chung K, Gao C, Gay J, Key B, Hansen G, Machajewski D, Platt KA, Sands AT et al (2007) Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc Natl Acad Sci USA 104: 11766–11771
19. Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J et al (2013) Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 45: 1345–1352
20. Do R, Stitziel NO, Won HH, Jørgensen AB, Duga S, Angelica Merlini P, Kiezun A, Farrall M, Goel A, Zuk O et al (2015) Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 518: 102–106
21. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, Erdmann J, Braund P, Engert JC, Bennett D et al (2009) Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302: 37–48
22. Erdmann J, Grosshennig A, Braund PS, König IR, Hengstenberg C, Hall AS, Diemert P, Kathiresan S, Wright B, Tregouet DA et al (2009) New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet 41: 280–282
23. Erdmann J, Stark K, Esslinger UB, Rumpf PM, Koesling D, De Wit C, Kaiser FJ, Braunholz D, Medack A, Fischer M et al (2013) Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature 504: 432–436
24. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, Hutabarat RM, Clausen VA, Karsten V, Cehelsky J et al (2014) Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383: 60–68
25. Flister MJ, Hoffman MJ, Lemke A, Prisco SZ, Rudemiller N, O'Meara CC, Tsaih SW, Moreno C, Geurts AM, Lazar J et al (2015) SH2B3 is a genetic determinant of cardiac inflammation and fibrosis. Circ Cardiovasc Genet 8: 294–304
26. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C et al (2013) STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41: D808–D815
27. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, Fan Y et al (2008) Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 105: 11915–11920
28. Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, Geary RS, Hughes SG, Viney NJ, Graham MJ et al (2015) Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 373: 438–447
29. 1000 Genomes Project Consortium (2012) An integrated map of genetic variation from 1,092 human genomes. Nature 491: 56–65
30. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing Z-C, Keogh AM, Langleben D, Kilama MO, Fritsch A et al (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369: 330–340
31. Gudbjartsson DF, Bjornsdottir US, Halapi E, Helgadottir A, Sulem P, Jonsdottir GM, Thorleifsson G, Helgadottir H, Steinthorsdottir V, Stefansson H et al (2009) Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 41: 342–347
32. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, Jonasdottir A, Sigurdsson A, Baker A, Palsson A et al (2007) A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316: 1491–1493
33. Holdt LM, Beutner F, Scholz M, Gielen S, Gäbel G, Bergert H, Schuler G, Thiery J, Teupser D (2010) ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arterioscler Thromb Vasc Biol 30: 620–627
34. Holdt LM, Hoffmann S, Sass K, Langenberger D, Scholz M, Krohn K, Finstermeier K, Stahringer A, Wilfert W, Beutner F et al (2013) Alu elements in ANRIL non-coding RNA at chromosome 9p21 modulate atherogenic cell functions through trans-regulation of gene networks. PLoS Genet 9: e1003588
35. Huan T, Zhang B, Wang Z, Joehanes R, Zhu J, Johnson AD, Ying S, Munson PJ, Raghavachari N, Wang R et al (2013) A systems biology framework identifies molecular underpinnings of coronary heart disease. Arterioscler Thromb Vasc Biol 33: 1427–1434
36. Hughes M, Saarela O, Stritzke J, Kee F, Silander K, Klopp N, Kontto J, Karvanen J, Willenborg C, Salomaa V et al (2012) Genetic markers enhance coronary risk prediction in men: the MORGAM prospective cohorts. PLoS ONE 7: e40922
37. Hunt KA, Zhernakova A, Turner G, Heap GAR, Franke L, Bruinenberg M, Romanos J, Dinesen LC, Ryan AW, Panesar D et al (2008) Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 40: 395–402
38. IBC 50K CAD Consortium (2011) Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genet 7: e1002260
39. International Consortium for Blood Pressure Genome-Wide Association Studies (2011) Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478: 103–109
40. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD (1999) Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 100: 1423–1431
41. Jameson JL, Longo DL (2015) Precision medicine–personalized, problematic, and promising. N Engl J Med 372: 2229–2234
42. Kamburov A, Stelzl U, Lehrach H, Herwig R (2013) The ConsensusPathDB interaction database: 2013 update. Nucleic Acids Res 41: D793–D800
43. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J (1961) Factors of risk in the development of coronary heart disease–six year follow-up experience. The Framingham Study. Ann Intern Med 55: 33–50
44. Kawashima S (2004) Malfunction of vascular control in lifestyle-related diseases: endothelial nitric oxide (NO) synthase/NO system in atherosclerosis. J Pharmacol Sci 96: 411–419
45. Kessler T, Zhang L, Liu Z, Yin X, Huang Y, Wang Y, Fu Y, Mayr M, Ge Q, Xu Q et al (2015) ADAMTS-7 inhibits re-endothelialization of injured arteries and promotes vascular remodeling through cleavage of thrombospondin-1. Circulation 131: 1191–1201
46. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL, Morrison AC, Johnson AD, Aspelund T et al (2009) Genome-wide association study of blood pressure and hypertension. Nat Genet 41: 677–687
47. Liang H, Chaparro-Riggers J, Strop P, Geng T, Sutton JE, Tsai D, Bai L, Abdiche Y, Dilley J, Yu J et al (2012) Proprotein convertase subtilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther 340: 228–236
48. Lieb W, Jansen H, Loley C, Pencina MJ, Nelson CP, Newton-Cheh C, Reilly MP, Assimes TL, Boerwinkle E, Hall AS et al (2013) Genetic predisposition to higher blood pressure increases coronary artery disease risk. Hypertension 61: 995–1001
49. Lu X, Wang L, Chen S, He L, Yang X, Shi Y, Cheng J, Zhang L, Gu CC, Huang J et al (2012) Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease. Nat Genet 44: 890–894
50. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U (1994) Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 330: 1041–1046
51. Mayer B, Erdmann J, Schunkert H (2007) Genetics and heritability of coronary artery disease and myocardial infarction. Clin Res Cardiol 96: 1–7
52. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR et al (2007) A common allele on chromosome 9 associated with coronary heart disease. Science 316: 1488–1491
53. Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, Nordio F, Hyde CL, Cannon CP, Sacks FM et al (2015) Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 385: 2264–2271
54. Melichar VO, Behr-Roussel D, Zabel U, Uttenthal LO, Rodrigo J, Rupin A, Verbeuren TJ, Kumar HSA, Schmidt HHHW (2004) Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci USA 101: 16671–16676
55. Mori T, Iwasaki Y, Seki Y, Iseki M, Katayama H, Yamamoto K, Takatsu K, Takaki S (2014) Lnk/Sh2b3 controls the production and function of dendritic cells and regulates the induction of IFN- -producing T cells. J Immunol 193: 1728–1736
56. Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, Sachs KV, Li X, Li H, Kuperwasser N, Ruda VM et al (2010) From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 466: 714–719
57. Myocardial Infarction Genetics Consortium (2009) Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 41: 334–341
58. Myocardial Infarction Genetics Consortium Investigators (2014) Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 371: 2072–2082
59. Nakada T-A, Russell JA, Boyd JH, Thair SA, Walley KR (2015) Identification of a nonsynonymous polymorphism in the SVEP1 gene associated with altered clinical outcomes in septic shock. Crit Care Med 43: 101–108
60. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J et al (2015) The support of human genetic evidence for approved drug indications. Nat Genet 47: 856–860
61. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, Najjar SS, Zhao J-H, Heath SC, Eyheramendy S et al (2009) Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 41: 666–676
62. Nichols M, Townsend N, Scarborough P, Rayner M (2014) Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J 35: 2950–2959
63. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, Saleheen D, Kyriakou T, Nelson CP, Hopewell JC et al (2015) A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease. Nat Genet 47: 1121–1130
64. Pasterkamp G, Schoneveld AH, van der Wal AC, Haudenschild CC, Clarijs RJ, Becker AE, Hillen B, Borst C (1998) Relation of arterial geometry to luminal narrowing and histologic markers for plaque vulnerability: the remodeling paradox. J Am Coll Cardiol 32: 655–662
65. Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN, Burnett MS, Devaney JM, Knouff CW, Thompson JR et al (2011) Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 377: 383–392
66. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M et al (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372: 1489–1499
67. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM et al (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372: 1500–1509
68. Salvi E, Kutalik Z, Glorioso N, Benaglio P, Frau F, Kuznetsova T, Arima H, Hoggart C, Tichet J, Nikitin YP et al (2012) Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase. Hypertension 59: 248–255
69. Salvi E, Kuznetsova T, Thijs L, Lupoli S, Stolarz-Skrzypek K, D'Avila F, Tikhonoff V, De Astis S, Barcella M, Seidlerova J et al (2013) Target sequencing, cell experiments, and a population study establish endothelial nitric oxide synthase (eNOS) gene as hypertension susceptibility gene. Hypertension 62: 844–852
70. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE et al (2007) Genomewide association analysis of coronary artery disease. N Engl J Med 357: 443–453
71. Sato-Nishiuchi R, Nakano I, Ozawa A, Sato Y, Takeichi M, Kiyozumi D, Yamazaki K, Yasunaga T, Futaki S, Sekiguchi K (2012) Polydom/SVEP1 is a ligand for integrin 91. J Biol Chem 287: 25615–25630
72. Schunkert H, Samani NJ (2008) Elevated C-reactive protein in atherosclerosis–chicken or egg? N Engl J Med 359: 1953–1955
73. Schunkert H, Götz A, Braund P, McGinnis R, Tregouet DA, Mangino M, Diemert P, Cambien F, Hengstenberg C, Stark K et al (2008) Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation 117: 1675–1684
74. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AFR, Barbalic M, Gieger C et al (2011) Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 43: 333–338
75. Schunkert H, Samani NJ (2015) Statin treatment: can genetics sharpen the focus? Lancet 385: 2227–2229
76. Schwanzer-Pfeiffer D, Rossmanith E, Schildberger A, Falkenhagen D (2010) Characterization of SVEP1, KIAA, and SRPX2 in an in vitro cell culture model of endotoxemia. Cell Immunol 263: 65–70
77. Smits PC, Pasterkamp G, van Ufford MAQ, Eefting FD, Stella PR, de Jaegere PPT, Borst C (1999) Coronary artery disease: arterial remodelling and clinical presentation. Heart 82: 461–464
78. Soranzo N, Spector TD, Mangino M, Kühnel B, Rendon A, Teumer A, Willenborg C, Wright B, Chen L, Li M et al (2009) A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet 41: 1182–1190
79. Stasch J-P, Hobbs AJ (2009) NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 191: 277–308
80. Stenina OI, Topol EJ, Plow EF (2007) Thrombospondins, their polymorphisms, and cardiovascular disease. Arterioscler Thromb Vasc Biol 27: 1886–1894
81. Stitziel NO, Stirrups KE, Masca NG, Erdmann J, Ferrario PG, König IR, Weeke PE, Webb TR, Auer PL, Schick UM et al (2016) Coding variation in ANGPTL4, LPL, and SVEP1 and risk of coronary disease. N Engl J Med 374: 1134–1144
82. Swirski FK, Nahrendorf M (2013) Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 339: 161–166
83. Takizawa H, Nishimura S, Takayama N, Oda A, Nishikii H, Morita Y, Kakinuma S, Yamazaki S, Okamura S, Tamura N et al (2010) Lnk regulates integrin αIIbβ3 outside-in signaling in mouse platelets, leading to stabilization of thrombus development in vivo. J Clin Invest 120: 179–190
84. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ et al (2010) Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466: 707–713
85. The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute (2014) Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 371: 22–31
86. Tregouet DA, König IR, Erdmann J, Munteanu A, Braund PS, Hall AS, Grosshennig A, Diemert P, Perret C, Desuremain M et al (2009) Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 41: 283–285
87. Von Hundelshausen P, Weber C (2007) Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 100: 27–40
88. Wang L, Zheng J, Bai X, Liu B, Liu C-J, Xu Q, Zhu Y, Wang N, Kong W, Wang X (2009) ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries. Circ Res 104: 688–698
89. Wang L, Zheng J, Du Y, Huang Y, Li J, Liu B, Liu C-J, Zhu Y, Gao Y, Xu Q et al (2010) Cartilage oligomeric matrix protein maintains the contractile phenotype of vascular smooth muscle cells by interacting with alpha(7)beta(1) integrin. Circ Res 106: 514–525
90. Wang F, Xu CQ, He Q, Cai JP, Li XC, Wang D, Xiong X, Liao YH, Zeng QT, Yang YZ et al (2011) Genome-wide association identifies a susceptibility locus for coronary artery disease in the Chinese Han population. Nat Genet 43: 345–349
91. Yang J, Bakshi A, Zhu Z, Hemani G, Vinkhuyzen AA, Lee SH, Robinson MR, Perry JR, Nolte IM, van Vliet-Ostaptchouk JV et al (2015) Genetic variance estimation with imputed variants finds negligible missing heritability for human height and body mass index. Nat Genet 47: 1114–1120.
92. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364: 937–952
93. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG (2008) Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359: 1897–1908